Persistent elevation of blood sugar contributes to dysfunction.
Persistent elevation of blood sugar contributes to dysfunction.
The National Food and Drug Administration and Control Agency (NAFDAC) has shown the manufacture of a glucose meter that is used to measure blood glucose levels through Colexa Biosensor Limited, a subsidiary of Codix Pharma Limited, in Lagos.
A glucometer, also known as a glucometer or glucometer, is a medical device (in vitro diagnostics) used to measure the approximate concentration of glucose in the blood. This is a key to at-home glucose control.
Persistent rise in blood sugar levels leads to glucose toxicity, contributing to cellular disruption and clustered pathology as complications of diabetes.
Through NAFDAC’s media representative, Sayo Akintola, he quoted the agency’s director general, Prof. Mojisola Adeyeye, who revealed this during a field trip to the facilities of the first in vitro diagnostic (IVD) production site of a fitness generation company, Colexa Biosensor. Limited to Lagos.
He said that while there are other ways to test and measure blood glucose, adding the use of blood glucose meters, the manufacture of blood glucose meters and strips in Nigeria will revolutionize healthcare and have a significant effect on people’s lives. diabetes in Africa and beyond.
However, it is under pressure from the need for high-quality products to always meet world-class criteria, in order to compete advantageously with Europe and the United States at affordable prices.
The CEO said NAFDAC would review the FDA’s globally accepted criteria, adding that the company would work with the company for help with regulatory compliance.
For an African medical device company, he said the feat would greatly contribute to the physical fitness of nations through access to innovative, quality, technology-based fitness responses for disease prevention, early diagnosis and management.
Adeyeye called on the company to pay more attention to the local market by manufacturing quality products that are readily available to Nigerians before venturing into the global market with its 12 locations in Africa, adding the UAE and the UK.
He further told the company that NAFDAC would only allow the export of quality products that are proven to be and effective.
According to the company, with the opening of a new factory in Shagamu, things will improve when this plant becomes operational in October next year. As for supplying foreign partners, what will sell the product is the quality.
The head of NAFDAC, however, recommended that the company create a research team that will strive to monitor selectivity and sensitivity once it enters the Nigerian market, adding that this goes hand in hand with commercialization.
The results of this study will be guided and shared with NAFDAC.
According to her, it will be a lot when NAFDAC reaches WHO maturity level 4, adding that at this stage, little time will be spent on prequalification programs presented after graduation.
As a leading manufacturer of medical devices and in vitro diagnostics in sub-Saharan Africa, Adeyeye congratulated the company for achieving firsts in several projects across its operations, being the first to introduce malaria Immediate Diagnosis Verification (RDT) kits into the national malaria elimination framework. . program, which has accelerated the ability to control and treat malaria in a timely manner.
Onyebuchi Ezigbo
Easily access key global news with a special focus on Africa. In addition to the more sensible stories of the day, we like to accentuate positive stories about Africa in all genres, adding politics, business, commerce, science, sports, art and culture, show business. and fashion.
We broadcast 24 hours a day from our studios in London and New York and can watch it here in the UK and across Europe on the Sky platform (Sky channel 516), Freeview (channel 136) as well as in the US and across the US. It will be available in the U. S. on the Centric channel and also on the Hot bird platform, which broadcasts to Europe, North Africa and the Middle East.
© 2023 Arise News – Part of Arise Media Group.